Abstract
IntroductionRaynaud's phenomenon (RP) is a vasospastic condition that carries a significant burden of pain and disability. When conventional therapies are not sufficiently effective, the need arises to explore other therapeutic alternatives such as interdigital botulinum toxin (BT) injection. ObjectiveTo determine clinical improvement in patients with RP (number of daily episodes, Visual Analogue Scale (VAS) during episodes, duration of episodes, and Raynaud Condition Score). Materials and methodsObservational, descriptive, retrospective study of patients with RP who received ultrasound-guided interdigital injection of typeA BT. Data from post-procedure controls (months1, 3, and6) were obtained, and analysis was performed using the Wilcoxon test through the StatPlus programme. ResultsThe study was conducted on 8 patients (100% female) with a mean age of 48.5years, all of whom had RP secondary to a systemic disease (87.5% systemic sclerosis). Significant differences were observed (median and interquartile range) in the number of RP episodes in the first month (P=.043). The pain VAS for each episode decreased in the first month (P=.027) and in the third month (P=.043). Differences were found in the Raynaud condition score in the first month (P=.027) and the third month (P=.043). ConclusionsUltrasound-guided interdigital injection of typeA BT could be an adjuvant treatment for patients with RP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
